Text Size

Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer

This study has been completed.
Sponsor:
Information provided by:
Medical University of South Carolina
ClinicalTrials.gov Identifier:
NCT00287963
First received: February 6, 2006
Last updated: April 26, 2012
Last verified: April 2012
History of Changes
  Purpose

RATIONALE: Drugs used in chemotherapy, such as topotecan and vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of topotecan when given together with vinorelbine in treating patients with recurrent lung cancer.


Condition Intervention Phase
Lung Cancer
 Drug: topotecan hydrochloride
Drug: vinorelbine tartrate
 Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: A Phase I Study of Topotecan in Combination With Vinorelbine in Recurrent Lung Cancer

Resource links provided by NLM:

MedlinePlus related topics: Cancer Lung Cancer
U.S. FDA Resources

Further study details as provided by Medical University of South Carolina:

Primary Outcome Measures:
  • Maximum tolerated dose [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Response rate, stable disease rate, and time to progression by RECIST criteria on day 1 of each course [ Designated as safety issue: No ]

Estimated Enrollment: 36
Study Start Date: February 2004
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

Primary

  • Determine the maximum tolerated dose of topotecan when combined with vinorelbine ditartrate in patients with recurrent lung cancer.

Secondary

  • Assess the response and stable disease rates and the time to disease progression among treated patients.

OUTLINE: This is a dose-escalation study of topotecan.

Patents receive vinorelbine ditartrate IV over 8-10 minutes and topotecan IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which ≥ 2 of 6 patients experience dose-limiting toxicity.

After completion of study treatment, patients are followed periodically.

PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed lung cancer

    • All histologic types eligible
    • Recurrent or progressive disease after ≥ 1 prior chemotherapy regimen with or without radiotherapy

PATIENT CHARACTERISTICS:

  • ECOG performance status (PS) ≤ 2
  • Karnofsky PS ≥ 60%
  • Absolute neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Total bilirubin ≤ 1.5 mg/dL
  • Creatinine ≤ 1.5 mg/dL
  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • No other active invasive malignancy

  • No uncontrolled illness including, but not limited to:

    • Ongoing or active infection
    • Symptomatic congestive heart failure
    • Unstable angina pectoris
    • Cardiac arrhythmia
  • No psychiatric illness/social situation that would limit compliance with study requirements
  • No history of allergic reactions attributed to compounds of similar chemical or biologic composition to topotecan or vinorelbine ditartrate

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • At least 2 weeks since prior radiotherapy
  • No prior therapy with topotecan or vinorelbine ditartrate
  • No chemotherapy within the past 4 weeks (6 weeks for nitrosoureas or mitomycin C)
  • Recovered from agents administered > 4 weeks earlier
  • No other concurrent investigational agents
  • No concurrent palliative radiotherapy
  • No other concurrent anticancer therapies or agents

  • No concurrent hormones or other chemotherapy except for the following:

    • Steroids for adrenal failure
    • Hormones for nondisease-related conditions (e.g., insulin for diabetes)
    • Intermittent dexamethasone as an antiemetic
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00287963

Locations
United States, South Carolina
Hollings Cancer Center at Medical University of South Carolina
Charleston, South Carolina, United States, 29425
Sponsors and Collaborators
Medical University of South Carolina
Investigators
Study Chair: Andrew S. Kraft, MD Medical University of South Carolina
  More Information

Publications:

ClinicalTrials.gov Identifier: NCT00287963     History of Changes
Other Study ID Numbers: CDR0000454919, MUSC-104864/725, GSK-100780
Study First Received: February 6, 2006
Last Updated: April 26, 2012
Health Authority: United States: Federal Government

Keywords provided by Medical University of South Carolina:
adenocarcinoma of the lung
adenosquamous cell lung cancer
bronchoalveolar cell lung cancer
combined type small cell lung cancer
intermediate type small cell lung cancer
 large cell lung cancer
lymphocyte-like type small cell lung cancer
recurrent non-small cell lung cancer
recurrent small cell lung cancer
squamous cell lung cancer

Additional relevant MeSH terms:
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Vinorelbine
Vinblastine
Topotecan
Antineoplastic Agents, Phytogenic
 Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors

ClinicalTrials.gov processed this record on May 22, 2013